Amylyx Pharmaceuticals, Inc. Common Stock
$32.41
-$1.53 (-4.51%)
$32.25Day Range$34.21
Key Statistics
Market Cap
$4.33B
Shares Outstanding
127.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 7, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$34.21
Day High
$34.21
Day Low
$32.25
Volume
2.05M
VWAP
$32.63
Prev Close
$33.94
Transactions
--
Acc. Volume
--
About Amylyx Pharmaceuticals, Inc. Common Stock
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
PHARMACEUTICAL PREPARATIONSSIC 2834136 employees55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA, 02142617-682-0917IPO Jan 7, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001658551
- Composite FIGI
- BBG00DP10YT5
- Share Class FIGI
- BBG00DP10YW1
- Ticker Root
- AMLX
- SIC Code
- 2834
About Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) Stock
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) closed the 2026-09-18 session at $32.41, down 4.51% versus the previous close (-1.53). The stock opened at $34.21 and traded between $32.25 and $34.21 during that session. Session trading volume was 2.0M shares. The volume-weighted average price (VWAP) is $32.63.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Amylyx Pharmaceuticals, Inc. Common Stock has a market capitalization of $4.33 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. AMLX is listed on the XNAS exchange. The company employs approximately 136 people. Amylyx Pharmaceuticals, Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2022-01-07.
On this page you can find market AMLX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.